Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in Chinese - a preliminary report
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Metabolic complications are common with tacrolimus therapy. Recent evidence suggests that there is ethnical variability in the side-effect profile of tacrolimus. We performed an open-label study to examine the metabolic profile of tacrolimus-based immunosuppressive therapy in 10 consecutive adult Chinese patients after cadaveric renal transplantation. One case withdrew because of parvovirus infection. The mean age of the remaining nine cases was 33 +/- 2.9 yr. Mean tacrolimus whole blood trough level at 0 and 12 months were 11.4 +/- 1.8 and 7.0 +/- 0.7 ng/mL, respectively. The dosage at corresponding time points were 0.31 +/- 0.001 and 0.10 +/- 0.003 mg/kg, respectively. We found no difference in lipid profile, blood pressure control, and most importantly, fasting glucose level, before and I yr after tacrolimus therapy. Standard 75-g oral glucose tolerance test and whole blood HbA1c level were normal in all patients. Our preliminary data suggest good short-term safety among Chinese renal transplantation recipients after tacrolimus-based immunosuppressants, with a very low incidence of hyperglycemia, hypertension and dyslipidemia. The long-term implications and the underlying explanation for this ethnical difference require further investigations.
著者Chow KM, Szeto CC, Li PKT
期刊名稱Clinical Transplantation
出版年份2002
月份2
日期1
卷號16
期次1
出版社BLACKWELL MUNKSGAARD
頁次39 - 42
國際標準期刊號0902-0063
語言英式英語
關鍵詞Chinese; metabolic control; post-transplant diabetes mellitus; tacrolimus
Web of Science 學科類別Surgery; SURGERY; Transplantation; TRANSPLANTATION

上次更新時間 2021-20-10 於 00:30